Accendra HealthACH +0.28%61 3-Year RORE % is 70.12 as of Mar. 2026. GuruFocus rates ACH with a GF Score™ of 61/100 and a GF Value™ of $5.02 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 111 Medical Distribution companies, Accendra Health ranks better than 89.19% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Accendra Health's 3-Year RORE % for the quarter that ended in Mar. 2026 was 70.12%.
The industry rank for Accendra Health's 3-Year RORE % or its related term are showing as below:
ACH's 3-Year RORE % is ranked better than 89.19% of 111
companies
in the Medical Distribution industry
Industry Median: 14.45
vs ACH: 70.12
Accendra Health (NYSE:ACH) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Accendra Health 3-Year RORE % Related Terms
Accendra Health 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Accendra Health's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Accendra Health's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accendra Health 3-Year RORE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Accendra Health's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Accendra Health's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Accendra Health (ACH) has a 3-Year RORE % of 70.12 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Accendra Health and its competitors. According to the industry distribution chart, Accendra Health ranks #12 out of 111 companies in the Medical Distribution industry, placing it in the top 10.8%.
Is Accendra Health's 3-Year RORE % too high?
Accendra Health's current 3-Year RORE % is 70.12. The Medical Distribution industry median 3-Year RORE % is 14.45. Accendra Health's value of 70.12 is 385.3% above this industry median. Based on the distribution chart, Accendra Health ranks #12 out of 111 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Accendra Health has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Accendra Health's 3-Year RORE % compare to FOCL and YI?
According to the Medical Distribution industry distribution chart, Accendra Health ranks #12 out of 111 companies for 3-Year RORE %. This places Accendra Health in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 14.45. Accendra Health's value of 70.12 is 385.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Distribution company?
The median 3-Year RORE % among Medical Distribution companies is 14.45, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accendra Health's current 3-Year RORE % of 70.12 is 385.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Accendra Health and its competitors. For the Medical Distribution industry, the median 3-Year RORE % is 14.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accendra Health's current 3-Year RORE % is 70.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accendra Health stock overvalued right now?
Based on GuruFocus' analysis, Accendra Health (ACH) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.02, compared to a current price of $3.59 — trading 28.5% below its estimated fair value. The current 3-Year RORE % is 70.12 and 385.3% above the Medical Distribution industry median of 14.45. Accendra Health's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Accendra Health (ACH), the current 3-Year RORE % is 70.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Accendra Health (ACH) Overvalued in 2026?
Based on GuruFocus' analysis, Accendra Health stock appears to be undervalued.
The current stock price of $3.59 is trading 28.5% below its estimated GF Value™ of $5.02.
GuruFocus considers Accendra Health to be Modestly Undervalued.
Key valuation signals for ACH:
3-Year RORE %: 70.12
GF Value™: $5.02 vs. price of $3.59 (28.5% below fair value)
Industry Position: 385.3% above the Medical Distribution median (#12 of 111)
No single metric tells the full story. See the ACH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.
61GF Score
Get the complete analysis for ACH
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACH has been successfully added to your 
